文献速递乳腺癌

靶向MDM2降解揭示p53失活三阴性乳腺癌的新脆弱点

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
PubMed 文献 · Cancer Discov · 2023-01-01

研究针对p53失活的三阴性乳腺癌(TNBC)设计了一种靶向MDM2的蛋白水解靶向嵌合体(PROTAC),该PROTAC以高亲和力结合并招募VHL,选择性降解MDM2。在p53突变/缺失的TNBC细胞二维/三维培养及患者来源外植体(包括复发肿瘤)中,MDM2缺失导致凋亡而不伤及正常细胞;小鼠异种移植模型中药物稳定、靶向有效且对正常细胞无毒,显著延长生存。转录组分析显示p53家族靶基因上调,TAp73的激活是MDM2-PROTAC诱导凋亡所必需。

要点

  • p53失活TNBC中MDM2是生存所必需,挑战现有MDM2/p53范式。
  • MDM2-PROTAC在细胞、患者外植体和小鼠模型中诱导肿瘤凋亡且不伤正常细胞。
  • TAp73激活介导MDM2-PROTAC诱导的凋亡,为潜在治疗策略。

核心结论

  • MDM2是p53失活TNBC细胞生存所必需,PROTAC靶向MDM2降解是创新潜在治疗策略且优于现有MDM2抑制剂。

研究设计与样本

  • 研究设计为体外二维/三维培养、TNBC患者外植体及小鼠异种移植模型的临床前研究。

主要发现

  • MDM2-PROTAC以高亲和力结合并招募VHL,选择性靶向MDM2进行蛋白酶体降解。
  • 在p53突变/缺失TNBC细胞及患者外植体(包括复发肿瘤)中,MDM2缺失导致凋亡而正常细胞不受影响。
  • MDM2-PROTAC在体内稳定,治疗TNBC异种移植小鼠显示肿瘤靶向疗效且对正常细胞无毒,显著延长生存。
  • 转录组分析显示p53家族靶基因上调,TAp73激活是MDM2-PROTAC诱导凋亡所必需。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chimera (PROTAC) to target it. Our PROTAC selectively targets MDM2 for proteasome-mediated degradation with high-affinity binding and VHL recruitment. MDM2 loss in p53 mutant/deleted TNBC cells in two-dimensional/three-dimensional culture and TNBC patient explants, including relapsed tumors, causes apoptosis while sparing normal cells. Our MDM2-PROTAC is stable in vivo, and treatment of TNBC xenograft-bearing mice demonstrates tumor on-target efficacy with no toxicity to normal cells, significantly extending survival. Transcriptomic analyses revealed upregulation of p53 family target genes. Investigations showed activation and a required role for TAp73 to mediate MDM2-PROTAC-induced apoptosis. Our data, challenging the current MDM2/p53 paradigm, show MDM2 is required for p53-inactivated TNBC cell survival, and PROTAC-targeted MDM2 degradation is an innovative potential therapeutic strategy for TNBC and superior to existing MDM2 inhibitors. SIGNIFICANCE: p53-inactivated TNBC is an aggressive, therapy-resistant, and lethal breast cancer subtype. We designed a new compound targeting an unexpected vulnerability we identified in TNBC. Our MDM2-targeted degrader kills p53-inactivated TNBC cells, highlighting the requirement for MDM2 in TNBC cell survival and as a new therapeutic target for this disease. See related commentary by Peuget and Selivanova, p. 1043. This article is highlighted in the In This Issue feature, p. 1027.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Adams CM, Mitra R, Xiao Y, et al. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. Cancer Discov. 2023. PMID: 36734633. doi:10.1158/2159-8290.CD-22-1131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。